TLR4 and Insulin resistance: Nicotinamide mononucleotide prevented CD36-mediated lipid accumulation and CD36-TLR4 interaction, thereby reducing inflammation, fibrosis, cardiac dysfunction, and whole-body insulin resistance [36].